Overall, our study shows the importance of IGF1R expression in CLL and its strong association with specific adverse clinical and biological features, confirming the interest for the study of this gene as a potential prognostic factor and its possible role as a therapeutic target in a specific group of CLL patients carrying trisomy 12 and NOTCH1 mutations. This evidence concerns the gene IGF1R and B-cell chronic lymphocytic leukemia.